A Randomized, Double-Blind Study to Assess Paclitaxel-Eluting Stents in Treatment of Longer Lesions (TAXUS VI)

This study has been completed.
Sponsor:
Information provided by:
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00297804
First received: February 27, 2006
Last updated: March 11, 2009
Last verified: February 2008
  Purpose

The clinical investigation is an international, prospective, multi-center, double-blind, randomized safety and efficacy trial. The purpose of this study is to evaluate the safety and effectiveness of the TAXUS(TM)Stent System with 1µg/mm2 (loaded drug/stent surface area) of paclitaxel incorporated into a moderate rate-release formulation of triblock copolymer carrier system in patients with a higher risk of target lesion revascularisation and restenosis.


Condition Intervention Phase
Coronary Artery Disease
Device: TAXUS Express Paclitaxel-Eluting Coronary Stent System
Device: Control stent
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: TAXUS VI - A Randomized, Double-Blind Study to Assess Paclitaxel-Eluting Stents in Treatment of Longer Lesions

Resource links provided by NLM:


Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Rate of TVR 9 months after index procedure [ Time Frame: 9 Months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • • Rates of composite Major Adverse Cardiac Events (MACE) and the individual components of MACE, assessed at 1, 3, 6 and 9 months after the study procedure and annually for 5 years (i.e., 1, 2, 3, 4, and 5 years after the study procedure). [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Stent thrombosis rate. [ Time Frame: 5 Years ] [ Designated as safety issue: Yes ]
  • Target Vessel Failure. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Clinical procedural success. [ Time Frame: Post procedure ] [ Designated as safety issue: Yes ]
  • Binary restenosis rate. [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
  • • Additional angiographic endpoints at 9 month angiographic follow-up [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
  • IVUS assessment in a subset of approximately 200 patients. At the baseline procedure (post-procedural) and at 9 month follow-up the absolute neointimal volume and the change in neointimal volume from post-procedure to follow-up will be analysed. [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]

Enrollment: 448
Study Start Date: May 2002
Study Completion Date: February 2008
Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Device: TAXUS Express Paclitaxel-Eluting Coronary Stent System
Paclitaxel-Eluting Coronary Stent System
Active Comparator: Arm 2 Device: Control stent
control stent

Detailed Description:

The ultimate goal of a paclitaxel eluting stent system is to prevent restenosis by blunting the initial response to stent implant injury and sustaining the arrested response until vascular healing has taken place.

The purpose of the TAXUS VI trial is to study the safety and efficacy of the TAXUS(TM)Stent under controlled trial circumstances and targets patients with a higher risk of target lesion revascularisation and restenosis. The study population will include longer lesions, smaller diameter vessels, multiple lesions in the same vessel, and allows for the use of up to 2 randomized study stents.

The clinical investigation will evaluate the safety and effectiveness of the TAXUS(TM)Stent with 1 µg/mm2 (loaded drug/stent surface area) of paclitaxel incorporated into a moderate rate-release formulation of a triblock copolymer carrier system for treatment of de novo coronary artery lesions.

Patients are stratified by site and presence or absence of medically treated diabetes mellitus and then randomized to receive either the TAXUS(TM)Stent or the uncoated EXPRESS(TM)stent.

The primary objective of the study is to show superior 9-month target vessel revascularization (TVR) rate for TAXUS(TM) Stent compared to uncoated Express(TM)control stent.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • General Inclusion Criteria

    1. Patient >or= 18 years old
    2. Eligible for percutaneous coronary intervention
    3. Documented stable angina pectoris or unstable angina pectoris with documented ischemia or documented silent ischemia
    4. Acceptable candidate for CABG
    5. Patient (or legal guardian) understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
    6. Willing to comply with all specified follow-up evaluations
  • Angiographic Inclusion Criteria

    1. Target lesion located within a single native coronary vessel
    2. Target lesion randomized to treatment with the study device may be composed of multiple lesions but must be completely coverable by up to 2 study stents (maximum allowable stent length of 48 mm).
    3. Cumulative target lesion length is >or= 18 mm and <or= 40 mm (visual estimate)
    4. RVD of >or= 2.5 mm to <or= 3.75 mm (visual estimate)
    5. Target lesion diameter stenosis >or=50% (visual estimate)
    6. Target lesion is de novo

Exclusion Criteria:

  • General Exclusion Criteria:

    1. Known sensitivity to paclitaxel
    2. Any previous or planned treatment with any anti-restenotic drug-coated or drug-eluting coronary stent (Note: previous or planned treatment with heparin or phosphorylcholine coated stents is acceptable, as long as the procedure with the stent meets the protocol defined criteria for staged procedures)
    3. Previous or planned treatment with intravascular brachytherapy in the target vessel
    4. MI within 72 hours prior to the study procedure and/or CK-MB >2x the local laboratory's upper limits of normal (refers to a measured value on the day of the study procedure)
    5. Left ventricular ejection fraction <25%
    6. Cerebrovascular Accident within the past 6 months
    7. Acute or chronic renal dysfunction (creatinine >1.7 mg/dl or >150 µmol/L)
    8. Contraindication to ASA, or to both clopidogrel and ticlopidine
    9. Leukopenia (leukocyte count <3.5 x 109/liter)
    10. Thrombocytopenia (platelet count <100,000/mm3)
    11. Active peptic ulcer or active gastrointestinal bleeding
    12. Known allergy to stainless steel
    13. Any prior true anaphylactic reaction to contrast agents
    14. Known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the study procedure
    15. Patient is currently taking colchicine
    16. Patient is currently, or has been treated with paclitaxel within 12 months of the study procedure
    17. Female of childbearing potential with a positive pregnancy test within 7 days before the study procedure, or lactating, or intends to become pregnant during the study
    18. Life expectancy of less than 24 months due to other medical conditions
    19. Co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
    20. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
  • Angiographic Exclusion Criteria

    1. Left main coronary artery disease (stenosis >50%), whether protected or unprotected
    2. Target lesion is ostial in location (within 3.0 mm of vessel origin)
    3. Target lesion(s) and/or target vessel proximal to the target lesion(s) is moderately or severely calcified by visual estimation
    4. Target lesion is located within or distal to a >60°bend in the vessel
    5. Target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >2.0 mm in diameter
    6. Target lesion is totally occluded Thrombolysis in MI (TIMI flow <or= 1)
    7. Angiographic presence of probable or definite thrombus
    8. Target vessel will be pre-treated with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00297804

Locations
Germany
HELIOS Clinic
Siegburg, Germany, 53721
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Principal Investigator: Eberhard Grube, MD HELIOS Clinic Siegburg, Germany
  More Information

No publications provided by Boston Scientific Corporation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Thomas Naeschen, Boston Scientific
ClinicalTrials.gov Identifier: NCT00297804     History of Changes
Other Study ID Numbers: S2009, TAXUS VI
Study First Received: February 27, 2006
Last Updated: March 11, 2009
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Boston Scientific Corporation:
Coronary Artery Disease
Percutaneous Coronary Intervention
Stent Implant
Drug-coated Stent

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Vascular Diseases
Paclitaxel
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on October 29, 2014